RxDoctor Payments Data

Nicole Nicome, MD

Internal Medicine · Brooklyn, NYNPI 1811171515

Payments from drug & device makers

$1,666in general payments, 2019–2025

Across 67 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$320
  • Novo Nordisk$227
  • Lilly USA, LLC$197
  • AstraZeneca$186
  • Viiv Healthcare Company$171
  • Astellas Pharma US Inc$145
  • plus $421 from 7 others

What the payments were for

  • Food & beverage$1,666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,666 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$89,740
Medicare patients
212
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$53,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,898
ProliaDenosumab12$20,341
OzempicSemaglutide21$19,794
EliquisApixaban16$12,575
Breo ElliptaFluticasone/Vilanterol11$6,444
Atorvastatin Calcium457$4,759
Albuterol Sulfate HfaAlbuterol Sulfate99$2,624
Levothyroxine Sodium154$1,988
Amlodipine Besylate283$1,796
Ezetimibe84$1,780
Rosuvastatin Calcium102$1,747
Valsartan67$1,573
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide33$1,557
Chlorthalidone84$1,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$197$53,94849 claims
GSKTrelegy Ellipta, Breo Ellipta$49$28,34236 claims
AmgenProlia$320$20,34112 claims
Novo NordiskOzempic$227$19,79421 claims
PfizerEliquis$65$12,57516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →